Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down - Should You Sell?

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $33.97, but opened at $32.64. Agios Pharmaceuticals shares last traded at $33.53, with a volume of 27,907 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Performance

The firm's 50-day moving average price is $35.76 and its two-hundred day moving average price is $43.50. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of 2.93 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.93% and a net margin of 2,051.38%. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -0.46 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.93% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Agios Pharmaceuticals by 7.1% in the fourth quarter. Ameritas Investment Partners Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after purchasing an additional 394 shares during the last quarter. Federated Hermes Inc. grew its position in shares of Agios Pharmaceuticals by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after purchasing an additional 582 shares during the last quarter. KBC Group NV grew its position in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 611 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Agios Pharmaceuticals by 6.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock valued at $539,000 after purchasing an additional 688 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.